Avitas Wealth Management LLC Acquires 1,086 Shares of DexCom, Inc. (NASDAQ:DXCM)

Avitas Wealth Management LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 20.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,475 shares of the medical device company’s stock after purchasing an additional 1,086 shares during the quarter. Avitas Wealth Management LLC’s holdings in DexCom were worth $434,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its holdings in shares of DexCom by 103.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,306 shares of the medical device company’s stock valued at $356,000 after purchasing an additional 2,692 shares in the last quarter. abrdn plc grew its position in shares of DexCom by 28.4% in the 3rd quarter. abrdn plc now owns 384,646 shares of the medical device company’s stock worth $25,842,000 after buying an additional 85,174 shares during the last quarter. Semanteon Capital Management LP purchased a new position in shares of DexCom in the 3rd quarter worth approximately $922,000. State of Alaska Department of Revenue grew its position in shares of DexCom by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 46,400 shares of the medical device company’s stock worth $3,110,000 after buying an additional 3,155 shares during the last quarter. Finally, Forsta AP Fonden grew its position in shares of DexCom by 16.6% in the 3rd quarter. Forsta AP Fonden now owns 83,700 shares of the medical device company’s stock worth $5,611,000 after buying an additional 11,900 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

DXCM opened at $71.80 on Thursday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The firm has a fifty day moving average price of $69.96 and a 200 day moving average price of $96.55. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a market cap of $28.55 billion, a P/E ratio of 46.32, a P/E/G ratio of 2.26 and a beta of 1.18.

Analyst Ratings Changes

DXCM has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Oppenheimer cut their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company boosted their target price on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Royal Bank of Canada dropped their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, Stifel Nicolaus boosted their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Six research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.